1.Exercise With a Novel Digital Device Increased Serum Anti-influenza Antibody Titers After Influenza Vaccination
Jun-Pyo CHOI ; Ghazal AYOUB ; Jarang HAM ; Youngmin HUH ; Seung Eun CHOI ; Yu-Kyoung HWANG ; Ji Yun NOH ; Sae-Hoon KIM ; Joon Young SONG ; Eu Suk KIM ; Yoon-Seok CHANG
Immune Network 2023;23(2):e18-
It has been reported that some exercise could enhance the anti-viral antibody titers after vaccination including influenza and coronavirus disease 2019 vaccines. We developed SAT-008, a novel digital device, consists of physical activities and activities related to the autonomic nervous system. We assessed the feasibility of SAT-008 to boost host immunity after an influenza vaccination by a randomized, open-label, and controlled study on adults administered influenza vaccines in the previous year. Among 32 participants, the SAT-008 showed a significant increase in the anti-influenza antibody titers assessed by hemagglutination-inhibition test against antigen subtype B Yamagata lineage after 4 wk of vaccination and subtype B Victoria lineage after 12 wk (p<0.05). There was no difference in the antibody titers against subtype “A.” The SAT-008 also showed significant increase in the plasma cytokine levels of IL-10, IL-1β, and IL-6 at weeks 4 and 12 after the vaccination (p<0.05). A new approach using the digital device may boost host immunity against virus via vaccine adjuvant-like effects.
2.Exploring sex differences in Korean emergency physicians using nationwide survey
Kyung Su BAE ; Kyung Hye PARK ; Ji Hun KANG ; Donghune KEY ; In Byung KIM ; Hong-jae KIM ; Song Yi PARK ; Beom Sok SEO ; In Hwan YEO ; Yoo Sang YOON ; Mi Jin LEE ; Eu Sun LEE ; Hyung Min LEE ; Daesung LIM ; Woo Jin JUNG ; Kwang Hyun CHO ; Youngmin JOO ; Chang Gun JEE ; Suk Jae CHOI ; JaeHun HAN
Journal of the Korean Society of Emergency Medicine 2022;33(4):11-19
Objective:
In this study, we compared differences based on the gender of Korean emergency physicians to provide basic data for future emergency medicine development plans.
Methods:
We used data from the emergency physician survey (2020) conducted by the Korean Society of Emergency Medicine. A total of 1,303 emergency physicians responded to the survey. We adjusted demographic data relating to age, position, and work duration as an emergency physician, which could affect the differences based on gender. After propensity score matching, we compared working hours, work burden, income, motives for applying for emergency medicine, and future plans of the emergency physicians by sex.
Results:
The total working hours per month and night shifts per month were higher in men compared to the women. The women felt more pressure in the following areas: number of emergency patients, relationships with administrative agencies, insufficient emergency medical technician manpower, patients’ compliance, and relationships with other emergency physicians. Monthly income was higher in men. Women placed a higher value on ‘Acquiring a range of knowledge’ and ‘Degree of interest in working in the emergency room’ than men as motivation for applying for positions in emergency medicine. Regarding future plans, women placed less value on income and more on having enough free time and avoiding burnout. The retirement age was about 3 years lower for women than for men.
Conclusion
This study revealed gender differences in working hours, income, motivation for applying for emergency medicine, work burden, and future plans. It is expected that these differences are caused by physical limitations and socio-cultural backgrounds. It is recommended that more detailed investigations be carried out through qualitative research. These results could help in gender considerations while hiring emergency physicians.
3.CORRIGENDUM: Diagnostic model for pancreatic cancer using a multi-biomarker panel
Yoo Jin CHOI ; Woongchang YOON ; Areum LEE ; Youngmin HAN ; Yoonhyeong BYUN ; Jae Seung KANG ; Hongbeom KIM ; Wooil KWON ; Young-Ah SUH ; Yongkang KIM ; Seungyeoun LEE ; Junghyun NAMKUNG ; Sangjo HAN ; Yonghwan CHOI ; Jin Seok HEO ; Joon Oh PARK ; Joo Kyung PARK ; Song Cheol KIM ; Chang Moo KANG ; Woo Jin LEE ; Taesung PARK ; Jin-Young JANG
Annals of Surgical Treatment and Research 2021;100(4):252-
4.Beneficial effects of posttransplant dipeptidyl peptidase-4 inhibitor administration after pancreas transplantation to improve β cell function
Hye-Won JANG ; Chang Hee JUNG ; Youngmin KO ; Seong Jun LIM ; Hye Eun KWON ; Joo Hee JUNG ; Hyunwook KWON ; Young Hoon KIM ; Sung SHIN
Annals of Surgical Treatment and Research 2021;101(3):187-196
Purpose:
Dipeptidyl peptidase-4 (DPP-4) inhibitors lower blood glucose levels and enhance the function of pancreatic βcells. Yet, it is unknown whether posttransplant administration of DPP4 inhibitors is beneficial for pancreas transplant recipients.
Methods:
We thus retrospectively analyzed the records of 312 patients who underwent pancreas transplantation between 2000 and 2018 at Asan Medical Center (Seoul, Korea) and compared the metabolic and survival outcomes according to DPP-4 inhibitor treatment.
Results:
The patients were divided into the no DPP-4 inhibitor group (n = 165; no treatment with DPP-4 inhibitors or treated for <1 month) and the DPP-4 inhibitor group (n = 147; treated with DPP-4 inhibitors for ≥1 month). There were no significant differences in levels of glucose, hemoglobin A1c, and insulin between the 2 groups during 36 months of follow-up. However, the level of C-peptide was significantly higher in the DPP-4 inhibitor group at 1, 6, and 24 months posttransplant (all P < 0.05). Moreover, the DPP-4 inhibitor group had significantly higher rates of overall (log-rank test, P = 0.009) and death-censored (log-rank test, P = 0.036) graft survival during a 15-year follow-up.
Conclusion
Posttransplant DPP-4 inhibitor administration may help improve the clinical outcomes including β cell function after pancreas transplantation.
5.Diagnostic model for pancreatic cancer using a multi-biomarker panel
Yoo Jin CHOI ; Woongchang YOON ; Areum LEE ; Youngmin HAN ; Yoonhyeong BYUN ; Jae Seung KANG ; Hongbeom KIM ; Wooil KWON ; Young-Ah SUH ; Yongkang KIM ; Seungyeoun LEE ; Junghyun NAMKUNG ; Sangjo HAN ; Yonghwan CHOI ; Jin Seok HEO ; Joon Oh PARK ; Joo Kyung PARK ; Song Cheol KIM ; Chang Moo KANG ; Woo Jin LEE ; Taesung PARK ; Jin-Young JANG
Annals of Surgical Treatment and Research 2021;100(3):144-153
Purpose:
Diagnostic biomarkers of pancreatic ductal adenocarcinoma (PDAC) have been used for early detection to reduce its dismal survival rate. However, clinically feasible biomarkers are still rare. Therefore, in this study, we developed an automated multi-marker enzyme-linked immunosorbent assay (ELISA) kit using 3 biomarkers (leucine-rich alpha-2-glycoprotein [LRG1], transthyretin [TTR], and CA 19-9) that were previously discovered and proposed a diagnostic model for PDAC based on this kit for clinical usage.
Methods:
Individual LRG1, TTR, and CA 19-9 panels were combined into a single automated ELISA panel and tested on 728 plasma samples, including PDAC (n = 381) and normal samples (n = 347). The consistency between individual panels of 3 biomarkers and the automated multi-panel ELISA kit were accessed by correlation. The diagnostic model was developed using logistic regression according to the automated ELISA kit to predict the risk of pancreatic cancer (high-, intermediate-, and low-risk groups).
Results:
The Pearson correlation coefficient of predicted values between the triple-marker automated ELISA panel and the former individual ELISA was 0.865. The proposed model provided reliable prediction results with a positive predictive value of 92.05%, negative predictive value of 90.69%, specificity of 90.69%, and sensitivity of 92.05%, which all simultaneously exceed 90% cutoff value.
Conclusion
This diagnostic model based on the triple ELISA kit showed better diagnostic performance than previous markers for PDAC. In the future, it needs external validation to be used in the clinic.
6.Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target
Jaewoo HONG ; Hyunjhung JHUN ; Yeo-Ok CHOI ; Afeisha S. TAITT ; Suyoung BAE ; Youngmin LEE ; Chang-seon SONG ; Su Cheong YEOM ; Soohyun KIM
Immune Network 2021;21(1):e8-
The global crisis caused by the coronavirus disease 2019 (COVID-19) led to the most significant economic loss and human deaths after World War II. The pathogen causing this disease is a novel virus called the severe acute respiratory syndrome coronavirus 2 (SARSCoV-2). As of December 2020, there have been 80.2 million confirmed patients, and the mortality rate is known as 2.16% globally. A strategy to protect a host from SARS-CoV-2 is by suppressing intracellular viral replication or preventing viral entry. We focused on the spike glycoprotein that is responsible for the entry of SARS-CoV-2 into the host cell. Recently, the US Food and Drug Administration/EU Medicines Agency authorized a vaccine and antibody to treat COVID-19 patients by emergency use approval in the absence of long-term clinical trials. Both commercial and academic efforts to develop preventive and therapeutic agents continue all over the world. In this review, we present a perspective on current reports about the spike glycoprotein of SARS-CoV-2 as a therapeutic target.
7.Traditional Chinese Medicine and Traditional Indonesian Medicine: A Comparative Review of Herbal Medicines Restricted in Pregnancy.
Purumea JUN ; Endang RAHMAT ; Chang-Hyun HAN ; Changsop YANG ; Youngmin KANG
Chinese journal of integrative medicine 2021;27(10):794-800
The decline in birth rates has become a very serious problem in various parts of the world. Many countries have implemented national programs for increasing birth rates, one of which involves the use of traditional medicine as an alternative solution. Among the fast-growing traditional medicines, traditional Chinese medicine (TCM) and traditional Indonesian medicine (TIM) have attracted a lot of demand globally. Here, we analyzed and compared the herbal medicines from TCM and TIM that must be avoided by pregnant women for preventing miscarriage and maintaining safety during pregnancy and the postpartum period. This review uses data from official reports from the respective government and national and international electronic databases for analysis. Although TCM and TIM have their own characteristics of treatment, they also have some similarities in concept and treatment, especially those related to herbal medicines. This review can be used as a reference base to help pregnant women consume herbal medicines at appropriate conditions and doses.
Drugs, Chinese Herbal/therapeutic use*
;
Herbal Medicine
;
Humans
;
Indonesia
;
Medicine, Chinese Traditional
;
Plants, Medicinal
;
Pregnancy
8.CORRIGENDUM: Diagnostic model for pancreatic cancer using a multi-biomarker panel
Yoo Jin CHOI ; Woongchang YOON ; Areum LEE ; Youngmin HAN ; Yoonhyeong BYUN ; Jae Seung KANG ; Hongbeom KIM ; Wooil KWON ; Young-Ah SUH ; Yongkang KIM ; Seungyeoun LEE ; Junghyun NAMKUNG ; Sangjo HAN ; Yonghwan CHOI ; Jin Seok HEO ; Joon Oh PARK ; Joo Kyung PARK ; Song Cheol KIM ; Chang Moo KANG ; Woo Jin LEE ; Taesung PARK ; Jin-Young JANG
Annals of Surgical Treatment and Research 2021;100(4):252-
9.SARS-CoV-2 Omicron Mutation Is Faster than the Chase: Multiple Mutations on Spike/ACE2 Interaction Residues
Sinae KIM ; Tam T. NGUYEN ; Afeisha S. TAITT ; Hyunjhung JHUN ; Ho-Young PARK ; Sung-Han KIM ; Yong-Gil KIM ; Eun Young SONG ; Youngmin LEE ; Hokee YUM ; Kyeong-Cheol SHIN ; Yang Kyu CHOI ; Chang-Seon SONG ; Su Cheong YEOM ; Byoungguk KIM ; Mihai NETEA ; Soohyun KIM
Immune Network 2021;21(6):e38-
Recently, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (B.1.1.529) Omicron variant originated from South Africa in the middle of November 2021. SARS-CoV-2 is also called coronavirus disease 2019 (COVID-19) since SARS-CoV-2 is the causative agent of COVID-19. Several studies already suggested that the SARS-CoV-2 Omicron variant would be the fastest transmissible variant compared to the previous 10 SARS-CoV-2 variants of concern, interest, and alert. Few clinical studies reported the high transmissibility of the Omicron variant but there is insufficient time to perform actual experiments to prove it, since the spread is so fast. We analyzed the SARS-CoV-2 Omicron variant, which revealed a very high rate of mutation at amino acid residues that interact with angiostatin-converting enzyme 2. The mutation rate of COVID-19 is faster than what we prepared vaccine program, antibody therapy, lockdown, and quarantine against COVID-19 so far. Thus, it is necessary to find better strategies to overcome the current crisis of COVID-19 pandemic.
10.Beneficial effects of posttransplant dipeptidyl peptidase-4 inhibitor administration after pancreas transplantation to improve β cell function
Hye-Won JANG ; Chang Hee JUNG ; Youngmin KO ; Seong Jun LIM ; Hye Eun KWON ; Joo Hee JUNG ; Hyunwook KWON ; Young Hoon KIM ; Sung SHIN
Annals of Surgical Treatment and Research 2021;101(3):187-196
Purpose:
Dipeptidyl peptidase-4 (DPP-4) inhibitors lower blood glucose levels and enhance the function of pancreatic βcells. Yet, it is unknown whether posttransplant administration of DPP4 inhibitors is beneficial for pancreas transplant recipients.
Methods:
We thus retrospectively analyzed the records of 312 patients who underwent pancreas transplantation between 2000 and 2018 at Asan Medical Center (Seoul, Korea) and compared the metabolic and survival outcomes according to DPP-4 inhibitor treatment.
Results:
The patients were divided into the no DPP-4 inhibitor group (n = 165; no treatment with DPP-4 inhibitors or treated for <1 month) and the DPP-4 inhibitor group (n = 147; treated with DPP-4 inhibitors for ≥1 month). There were no significant differences in levels of glucose, hemoglobin A1c, and insulin between the 2 groups during 36 months of follow-up. However, the level of C-peptide was significantly higher in the DPP-4 inhibitor group at 1, 6, and 24 months posttransplant (all P < 0.05). Moreover, the DPP-4 inhibitor group had significantly higher rates of overall (log-rank test, P = 0.009) and death-censored (log-rank test, P = 0.036) graft survival during a 15-year follow-up.
Conclusion
Posttransplant DPP-4 inhibitor administration may help improve the clinical outcomes including β cell function after pancreas transplantation.

Result Analysis
Print
Save
E-mail